On January 12, 2026 (after trading hours), the company entered into a subscription agreement with the subscribers (LP Investment Holdings Group and Mr. Li Jun) to issue a total of 7.46 million H shares. The subscription price is set at HK$5.36 per share, representing a discount of approximately 17.79% compared to the closing price of HK$6.52 per H share on the Hong Kong Stock Exchange on that day. The net proceeds from the subscription are expected to be approximately HK$39.73 million, with 80% allocated for the research and development, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and oncology intervention, as well as potential overseas business expansion for the commercialization of these products; the remaining 20% is intended for the Group's general working capital purposes.